Table 1.
Counts of product labels and all linked claims
|
Drug |
Number of product labels |
Number of VANDFRT |
Number of DIKB inhibits/substrate |
ClinicalTrials.gov |
Published results |
||
|---|---|---|---|---|---|---|---|
| |
for products containing |
DDIs found for |
of assertions with evidence |
studies involving the |
from ClinicalTrials.gov |
||
| the drug | the drug | found for the drug | drug | studies involving the drug | |||
| |
|
Significant |
Critical |
Evidence for |
Evidence against |
|
|
|
Antidepressants |
|
|
|
|
|
|
|
| Amitriptyline |
57 |
16 |
8 |
0 |
0 |
1 |
1 |
| Amoxapine |
2 |
15 |
8 |
0 |
0 |
0 |
0 |
| Bupropion |
111 |
7 |
4 |
2 |
0 |
5 |
44 |
| Citalopram |
85 |
25 |
9 |
2* |
4* |
4 |
25 |
| Desipramine |
15 |
16 |
10 |
0 |
0 |
0 |
0 |
| Doxepin |
32 |
15 |
9 |
0 |
0 |
0 |
0 |
| Duloxetine |
17 |
26 |
8 |
3 |
4 |
4 |
4 |
| Escitalopram |
20 |
13 |
3 |
4* |
5* |
6 |
9 |
| Fluoxetine |
90 |
51 |
14 |
2 |
0 |
8 |
22 |
| Imipramine |
19 |
18 |
10 |
0 |
0 |
1 |
4 |
| Mirtazapine |
55 |
2 |
5 |
4 |
9 |
1 |
22 |
| Nefazodone |
5 |
39 |
20 |
3 |
6 |
0 |
0 |
| Nortriptyline |
29 |
16 |
11 |
0 |
0 |
3 |
24 |
| Paroxetine |
60 |
33 |
11 |
2 |
0 |
3 |
40 |
| Selegiline |
11 |
2 |
47 |
0 |
0 |
1 |
1 |
| Sertraline |
74 |
28 |
8 |
2 |
0 |
3 |
27 |
| Tranylcypromine |
2 |
3 |
61 |
0 |
0 |
3 |
71 |
| Trazodone |
38 |
8 |
10 |
1 |
0 |
2 |
2 |
| Trimipramine |
2 |
17 |
10 |
0 |
0 |
0 |
0 |
| Venlafaxine |
66 |
21 |
6 |
3 |
3 |
2 |
2 |
|
Antipsychotics |
|
|
|
|
|
|
|
| Aripiprazole |
15 |
4 |
0 |
2 |
13 |
3 |
3 |
| Clozapine |
9 |
29 |
2 |
3 |
1 |
3 |
9 |
| Olanzapine |
42 |
0 |
1 |
1 |
0 |
5 |
13 |
| Quetiapine |
33 |
8 |
0 |
1 |
9 |
4 |
9 |
| Risperidone |
71 |
13 |
0 |
2 |
1 |
23 |
70 |
| Ziprasidone |
22 |
54 |
23 |
2* |
9* |
1 |
6 |
|
Sedative Hypnotics |
|
|
|
|
|
|
|
| Eszopiclone |
11 |
7 |
0 |
1 |
7 |
1 |
1 |
| Zaleplon |
24 |
0 |
0 |
1 |
1 |
0 |
0 |
| Zolpidem | 85 | 0 | 0 | 2 | 0 | 0 | 0 |
*Citalopram, escitalopram, and ziprasidone were each mapped to one claim for which there was both supporting and refuting evidence in the DIKB. Counts of product labels for each drug and claims that were linked to drug product labeling from three Linked Data drug information sources.